SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.09-3.4%9:39 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (5357)1/7/2002 1:04:39 PM
From: Biomaven  Read Replies (1) of 52153
 
<ITMN>

And just to clarify for those who don't follow the trial closely:

The primary endpoint will be progression-free survival time (i.e., time from baseline to death or disease progression)

Even if Actimmune was 100% effective (which it isn't), then you would still get dropouts stemming from people hitting this endpoint, because the patients in the placebo arm would be dying or progressing. (The nature of the untreated disease is inexorable progression to death).

As to how many Actimmune patients are dropping out by reaching the endpoint, we'll have to wait for the trial results to find out. <g>

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News